Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in UroGen between July 27, 2023 and May 15, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ:URGN) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired UroGen securities between July 27, 2023 and May 15, 2025, both dates inclusive (the "Class Period"). Investors have until July 28, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.Click here to participate in the action.UroGen engages in the development and commercialization of solutions for specialty cancers. According to the complaint, UroGen's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate ...Full story available on Benzinga.com